NJ Judge Not Convinced Epidiolex Seller Lied To USPTO

By Dani Kass · January 11, 2024, 10:48 PM EST

A New Jersey federal judge on Thursday dismissed allegations that 19 Jazz Pharmaceuticals patents covering its epilepsy treatment Epidiolex aren't enforceable, saying there's no evidence that the company lied to the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. TEVA PHARMACEUTICALS, INC. et al

Case Number

Court

New Jersey

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

January 03, 2023

Recent Articles By Dani

November 06, 2024
How The Patent System May Look After Trump's Return
October 17, 2024
Justices Urged To Fix 'Novel Misreading' Of IP Safe Harbor
October 07, 2024
Fed. Circ. Questions If Safer OxyContin Profits Came From IP
September 27, 2024
Kappos' Bayh-Dole Warning To Clients Draws Debate
September 24, 2024
Novo Nordisk Tells Sens. Ozempic Costs Are Linked To PBMs
August 13, 2024
Entresto Release Delayed As Novartis Goes To Fed. Circ.
August 06, 2024
Fed. Circ. Told Edwards Filed Safe Harbor Suit With Bad Intent
July 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer Feedback
May 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor
April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor